Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PPM1D | O15297 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355841 | 0.88 | SLC7A5 (0.48) | LOXL2CYP4F2CYP4A11MRGPRX4PRMT5 | |
| SCHEMBL18173134 | 0.86 | LOXL2 (0.54) | LOXL2CYP4F2CYP4A11MRGPRX4PRKD1 | |
| SCHEMBL15830232 | 0.85 | PRMT5 (0.51) | MRGPRX4PRMT5PRKD1HIF1APPM1D | |
| SCHEMBL15888150 | 0.85 | SMN1; SMN2 (0.45) | CYP4F2CYP4A11MRGPRX4PRMT5PRKD1 | |
| SCHEMBL13730162 | 0.85 | SMYD3 (0.58) | LOXL2CYP4F2CYP4A11MRGPRX4ALDH1A1 | |
| SCHEMBL17308302 | 0.79 | ALDH1A1 (0.49) | PRMT5PRKD1ALDH1A1PDCD1CD274 | |
| SCHEMBL375093 | 0.79 | ALDH1A1 (0.76) | PRMT5ALDH1A1KDM1ALMNAPDCD1 | |
| SCHEMBL937158 | 0.78 | PRKD1 (0.68) | PRKD1PRKD3PRKD2 | |
| SCHEMBL16992091 | 0.78 | MEN1 (0.50) | PRKD1ALDH1A1KDM1APDCD1CD274 | |
| SCHEMBL28618913 | 0.77 | LMNA (0.55) | PRMT5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308121-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | LOXL2 3563/4885CYP4F2 2638/4885CYP4A11 2862/4885 |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | LOXL2 3242/4885CYP4F2 2628/4885CYP4A11 1567/4885 |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | LOXL2 3563/4885CYP4F2 2638/4885CYP4A11 2862/4885 |
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | LOXL2 4274/4885CYP4F2 1933/4885CYP4A11 1889/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | LOXL2 3563/4885CYP4F2 2638/4885CYP4A11 2862/4885 |
| US-10980794-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT6 | LOXL2 3563/4885CYP4F2 2638/4885CYP4A11 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.